Theriva Biologics, Inc. 8-K

What Happened

• Theriva Biologics, Inc. announced on January 12, 2026 (Form 8-K) that it will make several presentations to investors over the coming weeks and filed an updated investor presentation as Exhibit 99.1 to the 8-K.
• The presentation contains "safe harbor" language under the Private Securities Litigation Reform Act of 1995, indicating some slides include forward‑looking statements rather than historical facts.

Key Details

• Filing date: January 12, 2026 (Current Report on Form 8-K).
• Exhibit filed: Exhibit 99.1 — Presentation of Theriva Biologics, Inc., dated January 2026.
• The presentation will be used in multiple investor presentations over the next several weeks.
• The document includes forward‑looking statement disclaimers (PSLRA safe harbor language).

Why It Matters

• Investors should note the company is updating and circulating its investor presentation, which may include forward‑looking statements about plans, expectations or goals.
• The 8-K does not report financial results, executive changes, or transactions—only the distribution of an updated presentation.
• Retail investors should review Exhibit 99.1 directly for any new guidance, timelines, or material disclosures and keep in mind forward‑looking statements are subject to risks and uncertainties described in the company's public filings.